rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases.
|
30222690 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One case in a 6-year-old male was morphologically similar to the BRAF V600E mutation-positive adult cases and subsequently metastasized to the lungs; remarkably, the metastases then completely resolved on Braf targeted therapy.
|
31192863 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations between BRAF V600E and TERT promoter mutations and clinicopathological features, Tumor-Node-Metastasis stage, initial risk, response to therapy, follow-up, and final disease outcome were assessed according to American Thyroid Association 2015 criteria and the American Joint Committee on Cancer/Tumor-Node-Metastasis (8th edition) staging system.Median follow-up was 120 months.
|
31305897 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, there is no prognostic value of BRAF V600E mutation on overall survival in stage I-III melanoma patients, yet its presence might indicate a decreased risk for development of relapse and/or metastasis in stage III melanoma patients.
|
31058533 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We successfully treated a BRAF V600E-mutated anaplastic oligoastrocytoma with multiple extraneural metastases with vemurafenib and everolimus.
|
30462564 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
NRAS mutant/BRAF wild type metastatic deposits were identified in three patients, with one patient having a BRAF V600E mutant metastatic tumour.
|
31023480 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, there is no prognostic value of BRAF V600E mutation on overall survival in stage I-III melanoma patients, yet its presence might indicate a decreased risk for development of relapse and/or metastasis in stage III melanoma patients.
|
31058533 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
NRAS mutant/BRAF wild type metastatic deposits were identified in three patients, with one patient having a BRAF V600E mutant metastatic tumour.
|
31023480 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After controlling for the effect of MS status, there was no correlation of RNF43 frameshift mutation with distant metastasis (OR = 1.57 [0.75, 3.28]) and advanced TNM stages (OR = 0.98 [0.58, 1.67]), but RNF43 frameshift mutations still occur more frequently in right colon (OR = 2.58 [1.49, 4.47]) and with BRAF V600E mutation (OR = 1.94 [1.22, 3.10]).
|
31122752 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases.
|
30222690 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One case in a 6-year-old male was morphologically similar to the BRAF V600E mutation-positive adult cases and subsequently metastasized to the lungs; remarkably, the metastases then completely resolved on Braf targeted therapy.
|
31192863 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations between BRAF V600E and TERT promoter mutations and clinicopathological features, Tumor-Node-Metastasis stage, initial risk, response to therapy, follow-up, and final disease outcome were assessed according to American Thyroid Association 2015 criteria and the American Joint Committee on Cancer/Tumor-Node-Metastasis (8th edition) staging system.Median follow-up was 120 months.
|
31305897 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We successfully treated a BRAF V600E-mutated anaplastic oligoastrocytoma with multiple extraneural metastases with vemurafenib and everolimus.
|
30462564 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
|
29119584 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analysis of the metastatic tumor demonstrated clonal expansion of a BRAF V600E subpopulation.
|
29744614 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This metastasis was found to have BRAF V600E mutation.
|
29405341 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
|
29119584 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This metastasis was found to have BRAF V600E mutation.
|
29405341 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analysis of the metastatic tumor demonstrated clonal expansion of a BRAF V600E subpopulation.
|
29744614 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT.Similar results were confirmed in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism.
|
27880942 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases.
|
29120401 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinically, patients with V600K tumors experience distant metastases sooner and have an increased risk of relapse and shorter survival than patients with V600E tumors.
|
28858076 |
2017 |